News

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Programs

HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn, MD, PhD, as Chief Medical Officer, effective January 1, 2022. Dr. Horn will lead the company’s growing clinical operations, clinical development, regulatory affairs, medical affairs, biometrics and pharmacovigilance functions. After practicing pediatrics for nearly 20 years, Dr. Horn has spent more than two decades leading successful clinical programs for large and small biotech companies.

 

“Pat has extensive medical knowledge and clinical development experience to lead our drug HST5040 through clinical studies and regulatory activities for methylmalonic acidemia and propionic acidemia, two rare metabolic diseases with no effective treatment options,” said Jim Powers, chairman and CEO of HemoShear Therapeutics. “Pat’s experience building highly effective teams and shepherding rare disease drugs to market will be invaluable as we advance our pipeline of inherited rare disease therapies.”

Dr. Horn’s experience spans all phases of rare pediatric drug development, from Phase 1 through regulatory approval and product launch. Most recently, he served as Chief Medical Officer for Albireo Pharma, where he led the team that achieved accelerated marketing approvals in the US and Europe for BylvayTM in progressive familial intrahepatic cholestasis (PFIC).  He also designed and initiated pivotal clinical development programs in biliary atresia and Alagille syndrome.  Prior to Albireo, he led clinical development programs in hereditary angioedema, homocystinuria, and infectious disease. Dr. Horn has formal training and extensive experience in clinical pharmacology.  He received his MD and PhD from the University of Chicago and completed a pediatric residency at Boston Children’s Hospital. Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

“I am excited to join HemoShear’s dedicated team as we continue our current clinical trial and plan additional global studies of HST5040 to treat methylmalonic acidemia and propionic acidemia as well as make progress in our early stage pipeline,” said Dr. Horn. “I look forward to collaborating with our team and the metabolic disease community to raise awareness of clinical trial opportunities, encourage early diagnosis and make progress to improve health outcomes for patients born with these devastating disorders.”

Read more here.

Recent News

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals